Actinium Pharmaceuticals (ATNM) Cash & Equivalents (2011 - 2026)

Actinium Pharmaceuticals (ATNM) has reported Cash & Equivalents for 16 consecutive years, with $42.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Equivalents fell 35.5% year-over-year to $42.1 million; the TTM figure through Mar 2026 stood at $42.1 million (down 35.5% YoY), while the FY2025 annual figure was $48.0 million, down 34.16% from the prior year.
• Cash & Equivalents declined to $42.1 million in Q1 2026 per ATNM's latest filing, from $48.0 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $116.3 million in Q2 2022 and bottomed at $42.1 million in Q1 2026.
• Historically, Cash & Equivalents has averaged $79.1 million across 5 years, with a median of $78.7 million in 2024.
• Annual changes were most pronounced in 2022 — Cash & Equivalents jumped 41.26% — and 2026, when it slumped 35.5%.
• Actinium Pharmaceuticals' Cash & Equivalents stood at $108.9 million in 2022, then slipped by 29.6% to $76.7 million in 2023, then dropped by 4.92% to $72.9 million in 2024, then tumbled by 34.16% to $48.0 million in 2025, then retreated by 12.22% to $42.1 million in 2026.
• Business Quant data shows ATNM's Cash & Equivalents at $42.1 million in Q1 2026, $48.0 million in Q4 2025, and $53.4 million in Q3 2025.